HEMATOLOGY

A discussion on decision factors for switching to and deciding upon a second-line therapy, and an overview of the phase 3 REACH2 study with ruxolitinib for glucocorticoid-refractory acute graft-vs-host disease (GVHD).

Hematologist Rafael Fonseca comments on data demonstrated by the PEGASUS study in transplant-ineligible multiple myeloma and expectations for treating appropriate patients with the combination of daratumumab, lenalidomide, and dexamethasone vs other options moving forward.

Clinical updates from the phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma. 

Insight regarding the assessment of minimal residual disease in patients with multiple myeloma and using testing results to aid in treatment selection.

Key opinion leaders discuss treatment goals for frontline therapy in patients with acute graft-vs-host disease.

Rationale regarding the use of BCMA-targeted CAR T-cell therapy in relapsed/refractory multiple myeloma.

Expert physicians discuss the role and efficacy of JAK inhibitors in steroid-refractory graft-vs-host disease (GVHD).

Considerations for adding daratumumab to the combination of lenalidomide and dexamethasone to treat transplant-ineligible newly diagnosed multiple myeloma based on updated efficacy data from the phase 3 MAIA trial.

Mayo Clinic’s Rafael Fonseca, MD, comments on the benefits of newer therapies that are now available for patients with newly diagnosed transplant-ineligible multiple myeloma.

A discussion on the role on Janus kinase signaling in the pathogenesis of acute and chronic graft-vs-host disease (GVHD).

Deepu Madduri, MD, provides an overview of the treatment landscape for patients with triple-class refractory multiple myeloma.

Implications for assessing MRD status in patients with transplant-ineligible myeloma and treating appropriate patients with the combination of daratumumab, lenalidomide, and dexamethasone.

Recent updates from the ASH 2020 annual meeting on the phase 1b/2 CARTITUDE-1 trial for relapsed/refractory multiple myeloma.

Expert physicians discuss the rationale behind the clinical use of JAK inhibitors in acute GvHD (graft-versus-host disease), and provide an overview of recent clinical trial data for this treatment approach.

Saad Usmani, MD, speculates on the current progress in treating multiple myeloma, while providing a glimpse into the future of cutting-edge treatments.

Saad Usmani, MD, reflects on the impact the coronavirus pandemic has had on his practice and the treatment of patients with multiple myeloma overall.

The MAIA & PEGASUS Trial and Managing Patients Receiving DRd

Saad Usmani, MD, analyzes the efficacy and safety data results from the phase 3 MAIA study.

Saad Usmani, MD, discusses what first-line options are available for patients with multiple myeloma while highlighting the difficulties in defining high-risk characteristics associated with multiple myeloma.

Saad Usmani, MD, presents a case of a 75-year-old woman with multiple myeloma and describes the patient’s current prognosis.

Saad Usmani, MD, presents a case of a 75-year-old woman with multiple myeloma.

The submission of a Biologics License Application has been initiated seeking approval of JZP-458 as a part of a multi-agent chemotherapy regimen as treatment of adult and pediatric patients with acute lymphoblastic leukemia or lymphoblastic lymphoma who developed hypersensitivity or silent inactivation to E. coli-derived asparaginases.

The FDA granted approval to rituximab-arrx, a biosimilar to rituximab as treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis.

During a Targeted Oncology Case Based Peer Perspectives event, Miguel-Angel Perales, MD, discussed testing for risk stratification and treatment of graft-versus-host-disease based on the case of a 48-year-old man.

Following the 2020 ASH Annual Meeting, a number of hematology experts shared their insights on the most important data presented during the meeting with Targeted Oncology.